FOLH1 and neoplasm: In contrast, the reported LNCaP tumor uptake of [177Lu]Lu-PSMA-617 peaked at 1h post-injection (16.5±2.46 %IA/g) and gradually reduced to 12.3±5.52 %IA/g at 120h post-injection.